Psilocybin in Alzheimer's disease: a Phase 2 trial on PharmaTerminal's active board
Published 10/15/2026 · By Curebiology
A Phase 2 study of psilocybin in Alzheimer's disease appears at position 4 of the 15 active trials on PharmaTerminal this week, recorded on ClinicalTrials.gov as NCT07721467. The study is listed as recruiting, with an enrollment of 200 and an estimated completion date at the end of 2030. It is notable this week both for its position near the top of the board and for the intervention it records for the disease; the board is ordered by ClinicalTrials.gov last-update date, so its position reflects that ordering rather than any measure of interest.
What is being studied
The intervention recorded on the registry is psilocybin, and the condition is Alzheimer's disease. The record lists the study as Phase 2, its status field reads RECRUITING, and the enrollment figure entered is 200. As with the other entries on this board, the sponsor field is recorded as Unknown, so no sponsor is named in the entry as presented.
Stage and recorded endpoint
The primary endpoint is recorded as: Determine whether psilocybin enhances neuroplasticity (Neuroplasticity Composite Score (NPCS)). The registry also gives an estimated completion date of 2030-12-31. These are registry values quoted as entered; the post does not interpret them into outcomes and reports no results.
Where to track this
PharmaTerminal presents this record and the full board at https://pharmaterminal.aeah.ai/#/dashboard. The item sits in the Active Clinical Trials (dashboard) section, where the terminal brings together live Phase 2 and Phase 3 trials, its pipeline tracker and approvals. The dashboard at https://pharmaterminal.aeah.ai/#/dashboard is the place to watch whether this study's status, enrollment or endpoint changes as the record is updated upstream.
Source
Upstream record: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07721467. The same record is presented in PharmaTerminal at https://pharmaterminal.aeah.ai/#/dashboard.
This is a summary of public registry and aggregated data and is not medical or investment advice.